Colorectal Cancer Market Report and Forecast 2025-2034
Description
The colorectal cancer market was valued at USD 14.55 Billion in 2024, driven by the increasing prevalence of colorectal cancer and the growth in clinical trials across the 8 major markets. The market is expected to grow at a CAGR of 7.80% during the forecast period of 2025-2034, with the values likely to reach USD 30.84 Billion by 2034.
Colorectal Cancer Market Overview
Colorectal cancer develops in the tissues of the colon or rectum, located at the lower end of the digestive tract. It is estimated that 1 in 24 individuals are likely to develop the disease in their lifetime. Although counted as one of the most treatable diseases when caught in the early stages, colorectal cancer is considered the leading cause of cancer-related deaths in men. The rising incidence of colorectal cancer along with the increasing aging population is one of the primary factors contributing to the market growth. Increased regular screening programs and advancements in imaging techniques are also supporting the market expansion. Moreover, the rising introduction of targeted therapies, the shift towards combination therapies, and the growth in clinical trials evaluating new treatment options are poised to influence the market dynamics.
Colorectal Cancer Market Growth Drivers
Increasing Prevalence of Colorectal Cancer is Driving Market Growth
According to the American Cancer Society (ACS), around 152,810 new cases of colorectal cancer are estimated to occur in 2024 in the United States, out of which 81,540 cases are predicted to be of men and 71,270 cases will account for women. Further, colorectal cancer is reported as the second-leading cause of all cancer-related deaths in the country and is estimated to be responsible for 53,010 deaths. This increasing burden of colorectal cancer as a result of the growing aging populations and unhealthy lifestyle patterns is expected to fuel market growth.
Colorectal Cancer Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rise in Drug Approvals to Affect the Market Landscape Significantly
In June 2024, Bristol Myers Squibb announced that its combination therapy, which includes the oral drug Krazati along with cetuximab, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of colorectal cancer in patients with a specific gene mutation. Krazati was added to Bristol Myers’s oncology portfolio following the acquisition of Mirati Therapeutics by the company in January 2024 for USD 5.8 billion. The rise in regulatory approval of such effective treatments for colorectal cancer is projected to impact market growth.
Growing Adoption of Immunotherapy to Augment Colorectal Cancer Market Demand
One of the major market trends is the rising adoption of immunotherapy, such as immune checkpoint inhibitors (pembrolizumab (Keytruda) and nivolumab (Opdivo)) for the treatment of colorectal cancer. These checkpoint inhibitors are particularly effective for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors.
Increased Investments to Elevate the Colorectal Cancer Market Value
In November 2023, Nouscom, a Switzerland-based next-generation immunotherapy company, secured USD 72 million in a Series C funding round that was co-led by investors Bpifrance, M Ventures, and Andera Partners. The company plans to leverage the funds to support the development of its cancer vaccine clinical pipeline which also boasts a colorectal cancer vaccine. Such substantial investments to advance colorectal cancer therapies are set to elevate the market value in the coming years.
Advancements in Screening Methods to Boost Colorectal Cancer Market Size
The development of non-invasive screening methods, such as liquid biopsies and stool-based DNA tests is a significant trend poised to facilitate early detection and fuel market growth. In addition, artificial intelligence and machine learning are increasingly being integrated into colorectal cancer screening and diagnostic tools, which is likely to improve the accuracy of cancer detection and also contribute to market demand during the forecast period.
Colorectal Cancer Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type:
Market Segmentation Based on Cancer Type Represents Significant Market Share
The market segmentation by cancer type includes colorectal cancer adenocarcinoma and gastrointestinal carcinoid tumors, among others. Adenocarcinoma accounts for the majority of cases of colorectal cancer, originating in the glandular cells lining the inside of the colon and rectum. Early-stage adenocarcinoma is usually treated with surgery, but combination treatments are often needed to manage advanced cases. The rising availability of targeted therapies like bevacizumab (Avastin) and cetuximab (Erbitux) and immunotherapies like pembrolizumab (Keytruda) is projected to support the growth of this segment in the forecast period.
Colorectal Cancer Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share owing to the high incidence rate of colorectal cancer which drives the demand for screening, diagnostics, and therapies. The easy availability of advanced treatments including immunotherapies, targeted therapies, and advanced surgical techniques also supports the market growth. Moreover, increasing investments in clinical research and trials along with rising cancer screening initiatives are anticipated to propel the market expansion in the country.
Leading Players in the Colorectal Cancer Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AstraZeneca
AstraZeneca, headquartered in Cambridge, United Kingdom, is a global, science-led biopharmaceutical business that is actively involved in developing immunotherapy drugs and targeted therapies for various cancers. Its drug candidate AZD-9592 is under clinical development and currently undergoing Phase I trial for metastatic colorectal cancer.
Pfizer, Inc.
Pfizer is one of the leading players in the market with a strong presence in the oncology sector. Its oral small molecule kinase inhibitor BRAFTOVI® (encorafenib) in combination with cetuximab (ERBITUX®) is approved by the FDA for previously treated metastatic colorectal cancer with a BRAFV600E mutation in adult patients.
Novartis AG
Swiss multinational pharmaceutical company Novartis is focused on the development of targeted therapies that target specific cancer growth pathways. The company is actively investing in several clinical programs to test new agents and combination therapies for colorectal cancer. Novartis' drug candidate Gevokizumab (XOMA-052), a human-engineered IgG2 monoclonal antibody, is under clinical development for metastatic colorectal cancer.
Amgen Inc.
Amgen, headquartered in Thousand Oaks, California, has a dominant presence in the market and is well known for developing innovative human therapeutics for diseases with high unmet medical needs. The company is focusing on expanding its biosimilar portfolio to improve the accessibility and affordability of effective treatments.
Other key players in the market include F. Hoffmann-La Roche Ltd., GSK plc, Eli Lilly and Company, AbbVie Inc., and Teva Pharmaceuticals Ltd.
Key Questions Answered in the Colorectal Cancer Market Report
Colorectal Cancer Market Overview
Colorectal cancer develops in the tissues of the colon or rectum, located at the lower end of the digestive tract. It is estimated that 1 in 24 individuals are likely to develop the disease in their lifetime. Although counted as one of the most treatable diseases when caught in the early stages, colorectal cancer is considered the leading cause of cancer-related deaths in men. The rising incidence of colorectal cancer along with the increasing aging population is one of the primary factors contributing to the market growth. Increased regular screening programs and advancements in imaging techniques are also supporting the market expansion. Moreover, the rising introduction of targeted therapies, the shift towards combination therapies, and the growth in clinical trials evaluating new treatment options are poised to influence the market dynamics.
Colorectal Cancer Market Growth Drivers
Increasing Prevalence of Colorectal Cancer is Driving Market Growth
According to the American Cancer Society (ACS), around 152,810 new cases of colorectal cancer are estimated to occur in 2024 in the United States, out of which 81,540 cases are predicted to be of men and 71,270 cases will account for women. Further, colorectal cancer is reported as the second-leading cause of all cancer-related deaths in the country and is estimated to be responsible for 53,010 deaths. This increasing burden of colorectal cancer as a result of the growing aging populations and unhealthy lifestyle patterns is expected to fuel market growth.
Colorectal Cancer Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rise in Drug Approvals to Affect the Market Landscape Significantly
In June 2024, Bristol Myers Squibb announced that its combination therapy, which includes the oral drug Krazati along with cetuximab, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of colorectal cancer in patients with a specific gene mutation. Krazati was added to Bristol Myers’s oncology portfolio following the acquisition of Mirati Therapeutics by the company in January 2024 for USD 5.8 billion. The rise in regulatory approval of such effective treatments for colorectal cancer is projected to impact market growth.
Growing Adoption of Immunotherapy to Augment Colorectal Cancer Market Demand
One of the major market trends is the rising adoption of immunotherapy, such as immune checkpoint inhibitors (pembrolizumab (Keytruda) and nivolumab (Opdivo)) for the treatment of colorectal cancer. These checkpoint inhibitors are particularly effective for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors.
Increased Investments to Elevate the Colorectal Cancer Market Value
In November 2023, Nouscom, a Switzerland-based next-generation immunotherapy company, secured USD 72 million in a Series C funding round that was co-led by investors Bpifrance, M Ventures, and Andera Partners. The company plans to leverage the funds to support the development of its cancer vaccine clinical pipeline which also boasts a colorectal cancer vaccine. Such substantial investments to advance colorectal cancer therapies are set to elevate the market value in the coming years.
Advancements in Screening Methods to Boost Colorectal Cancer Market Size
The development of non-invasive screening methods, such as liquid biopsies and stool-based DNA tests is a significant trend poised to facilitate early detection and fuel market growth. In addition, artificial intelligence and machine learning are increasingly being integrated into colorectal cancer screening and diagnostic tools, which is likely to improve the accuracy of cancer detection and also contribute to market demand during the forecast period.
Colorectal Cancer Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type:
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Targeted Drug Therapy
- Others
- Colorectal Cancer Adenocarcinoma
- Gastrointestinal Carcinoid Tumors
- Others
- Hospitals
- Clinics
- Cancer Centers
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Cancer Type Represents Significant Market Share
The market segmentation by cancer type includes colorectal cancer adenocarcinoma and gastrointestinal carcinoid tumors, among others. Adenocarcinoma accounts for the majority of cases of colorectal cancer, originating in the glandular cells lining the inside of the colon and rectum. Early-stage adenocarcinoma is usually treated with surgery, but combination treatments are often needed to manage advanced cases. The rising availability of targeted therapies like bevacizumab (Avastin) and cetuximab (Erbitux) and immunotherapies like pembrolizumab (Keytruda) is projected to support the growth of this segment in the forecast period.
Colorectal Cancer Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share owing to the high incidence rate of colorectal cancer which drives the demand for screening, diagnostics, and therapies. The easy availability of advanced treatments including immunotherapies, targeted therapies, and advanced surgical techniques also supports the market growth. Moreover, increasing investments in clinical research and trials along with rising cancer screening initiatives are anticipated to propel the market expansion in the country.
Leading Players in the Colorectal Cancer Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AstraZeneca
AstraZeneca, headquartered in Cambridge, United Kingdom, is a global, science-led biopharmaceutical business that is actively involved in developing immunotherapy drugs and targeted therapies for various cancers. Its drug candidate AZD-9592 is under clinical development and currently undergoing Phase I trial for metastatic colorectal cancer.
Pfizer, Inc.
Pfizer is one of the leading players in the market with a strong presence in the oncology sector. Its oral small molecule kinase inhibitor BRAFTOVI® (encorafenib) in combination with cetuximab (ERBITUX®) is approved by the FDA for previously treated metastatic colorectal cancer with a BRAFV600E mutation in adult patients.
Novartis AG
Swiss multinational pharmaceutical company Novartis is focused on the development of targeted therapies that target specific cancer growth pathways. The company is actively investing in several clinical programs to test new agents and combination therapies for colorectal cancer. Novartis' drug candidate Gevokizumab (XOMA-052), a human-engineered IgG2 monoclonal antibody, is under clinical development for metastatic colorectal cancer.
Amgen Inc.
Amgen, headquartered in Thousand Oaks, California, has a dominant presence in the market and is well known for developing innovative human therapeutics for diseases with high unmet medical needs. The company is focusing on expanding its biosimilar portfolio to improve the accessibility and affordability of effective treatments.
Other key players in the market include F. Hoffmann-La Roche Ltd., GSK plc, Eli Lilly and Company, AbbVie Inc., and Teva Pharmaceuticals Ltd.
Key Questions Answered in the Colorectal Cancer Market Report
- What was the colorectal cancer market value in 2024?
- What is the colorectal cancer market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment type?
- What is the market breakup based on cancer type?
- Who are the major end users in the market?
- What are the major factors aiding the colorectal cancer market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of colorectal cancer affect the market landscape?
- What are the major colorectal cancer market trends?
- How does the expansion of treatment options impact the market size?
- Which treatment type will dominate the market share?
- Which cancer type is expected to have a high market value in the coming years?
- Which end user is projected to contribute to the highest market growth?
- Who are the key players involved in the colorectal cancer market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Colorectal Cancer Market Overview – 8 Major Markets
- 3.1 Colorectal Cancer Market Historical Value (2018-2024)
- 3.2 Colorectal Cancer Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Colorectal Cancer Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Colorectal Cancer Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Colorectal Cancer Market Landscape – 8 Major Markets
- 8.1 Colorectal Cancer Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Colorectal Cancer Market: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 8.2.2 Analysis by Cancer Type
- 9 Colorectal Cancer Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Colorectal Cancer Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Colorectal Cancer Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Colorectal Cancer Market (2018-2034) by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Chemotherapy
- 12.1.3 Radiation Therapy
- 12.1.4 Immunotherapy
- 12.1.5 Targeted Drug Therapy
- 12.1.6 Others
- 12.2 Colorectal Cancer Market (2018-2034) by Cancer Type
- 12.2.1 Market Overview
- 12.2.2 Colorectal Cancer Adenocarcinoma
- 12.2.3 Gastrointestinal Carcinoid Tumors
- 12.2.4 Others
- 12.3 Colorectal Cancer Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Clinics
- 12.3.4 Cancer Centers
- 12.3.5 Others
- 12.4 Colorectal Cancer Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Colorectal Cancer Market (218-2034)
- 13.1 United States Colorectal Cancer Market Historical Value (2018-2024)
- 13.2 United States Colorectal Cancer Market Forecast Value (2025-2034)
- 13.3 United States Colorectal Cancer Market (2018-2034) by Treatment Type
- 13.3.1 Market Overview
- 13.3.2 Chemotherapy
- 13.3.3 Radiation Therapy
- 13.3.4 Immunotherapy
- 13.3.5 Targeted Drug Therapy
- 13.3.6 Others
- 13.4 United States Colorectal Cancer Market (2018-2034) by Cancer Type
- 13.4.1 Market Overview
- 13.4.2 Colorectal Cancer Adenocarcinoma
- 13.4.3 Gastrointestinal Carcinoid Tumors
- 13.4.4 Others
- 13.5 United States Colorectal Cancer Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Clinics
- 13.5.4 Cancer Centers
- 13.5.5 Others
- 14 EU-4 and United Kingdom Colorectal Cancer Market (218-2034)
- 14.1 EU-4 and United Kingdom Colorectal Cancer Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Colorectal Cancer Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Colorectal Cancer Market (2018-2034) by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Chemotherapy
- 14.3.3 Radiation Therapy
- 14.3.4 Immunotherapy
- 14.3.5 Targeted Drug Therapy
- 14.3.6 Others
- 14.4 EU-4 and United Kingdom Colorectal Cancer Market (2018-2034) by Cancer Type
- 14.4.1 Market Overview
- 14.4.2 Colorectal Cancer Adenocarcinoma
- 14.4.3 Gastrointestinal Carcinoid Tumors
- 14.4.4 Others
- 14.5 EU-4 and United Kingdom Colorectal Cancer Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals
- 14.5.3 Clinics
- 14.5.4 Cancer Centers
- 14.5.5 Others
- 15 Japan Colorectal Cancer Market
- 15.1 Japan Colorectal Cancer Market Historical Value (2018-2024)
- 15.2 Japan Colorectal Cancer Market Forecast Value (2025-2034)
- 15.3 Japan Colorectal Cancer Market (2018-2034) by Treatment Type
- 15.3.1 Market Overview
- 15.3.2 Chemotherapy
- 15.3.3 Radiation Therapy
- 15.3.4 Immunotherapy
- 15.3.5 Targeted Drug Therapy
- 15.3.6 Others
- 15.4 Japan Colorectal Cancer Market (2018-2034) by Cancer Type
- 15.4.1 Market Overview
- 15.4.2 Colorectal Cancer Adenocarcinoma
- 15.4.3 Gastrointestinal Carcinoid Tumors
- 15.4.4 Others
- 15.5 Japan Colorectal Cancer Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospitals
- 15.5.3 Clinics
- 15.5.4 Cancer Centers
- 15.5.5 Others
- 16 India Colorectal Cancer Market
- 16.1 India Colorectal Cancer Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Colorectal Cancer Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Colorectal Cancer Market (2018-2034) by Treatment Type
- 16.3.1 Market Overview
- 16.3.2 Chemotherapy
- 16.3.3 Radiation Therapy
- 16.3.4 Immunotherapy
- 16.3.5 Targeted Drug Therapy
- 16.3.6 Others
- 16.4 India Colorectal Cancer Market (2018-2034) by Cancer Type
- 16.4.1 Market Overview
- 16.4.2 Colorectal Cancer Adenocarcinoma
- 16.4.3 Gastrointestinal Carcinoid Tumors
- 16.4.4 Others
- 16.5 India Colorectal Cancer Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospitals
- 16.5.3 Clinics
- 16.5.4 Cancer Centers
- 16.5.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Grants Analysis
- 19.1 Analysis by Year
- 19.2 Analysis by Amount Awarded
- 19.3 Analysis by Issuing Authority
- 19.4 Analysis by Grant Application
- 19.5 Analysis by Funding Institute
- 19.6 Analysis by NIH Departments
- 19.7 Analysis by Recipient Organization
- 20 Funding and Investment Analysis
- 20.1 Analysis by Funding Instances
- 20.2 Analysis by Type of Funding
- 20.3 Analysis by Funding Amount
- 20.4 Analysis by Leading Players
- 20.5 Analysis by Leading Investors
- 20.6 Analysis by Geography
- 21 Strategic Initiatives
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Supplier Landscape
- 22.1 Market Share by Top 5 Companies
- 22.2 AstraZeneca
- 22.2.1 Financial Analysis
- 22.2.2 Product Portfolio
- 22.2.3 Demographic Reach and Achievements
- 22.2.4 Companies News and Developments
- 22.2.5 Certifications
- 22.3 Pfizer, Inc.
- 22.3.1 Financial Analysis
- 22.3.2 Product Portfolio
- 22.3.3 Demographic Reach and Achievements
- 22.3.4 Companies News and Developments
- 22.3.5 Certifications
- 22.4 Novartis AG
- 22.4.1 Financial Analysis
- 22.4.2 Product Portfolio
- 22.4.3 Demographic Reach and Achievements
- 22.4.4 Companies News and Developments
- 22.4.5 Certifications
- 22.5 Amgen Inc.
- 22.5.1 Financial Analysis
- 22.5.2 Product Portfolio
- 22.5.3 Demographic Reach and Achievements
- 22.5.4 Companies News and Developments
- 22.5.5 Certifications
- 22.6 F-Hoffmann-La Roche Ltd.
- 22.6.1 Financial Analysis
- 22.6.2 Product Portfolio
- 22.6.3 Demographic Reach and Achievements
- 22.6.4 Companies News and Developments
- 22.6.5 Certifications
- 22.7 GSK plc
- 22.7.1 Financial Analysis
- 22.7.2 Product Portfolio
- 22.7.3 Demographic Reach and Achievements
- 22.7.4 Companies News and Developments
- 22.7.5 Certifications
- 22.8 Eli Lily and Company
- 22.8.1 Financial Analysis
- 22.8.2 Product Portfolio
- 22.8.3 Demographic Reach and Achievements
- 22.8.4 Companies News and Developments
- 22.8.5 Certifications
- 22.9 Teva Pharmaceuticals Ltd.
- 22.9.1 Financial Analysis
- 22.9.2 Product Portfolio
- 22.9.3 Demographic Reach and Achievements
- 22.9.4 Companies News and Developments
- 22.9.5 Certifications
- 22.10 AbbVie Inc.
- 22.10.1 Financial Analysis
- 22.10.2 Product Portfolio
- 22.10.3 Demographic Reach and Achievements
- 22.10.4 Companies News and Developments
- 22.10.5 Certifications
- 23 Colorectal Cancer Treatment Drugs - Distribution Model (Additional Insight)
- 23.1 Overview
- 23.2 Potential Distributors
- 23.3 Key Parameters for Distribution Partner Assessment
- 24 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
